On Friday, January 5, the Federal Trade Commission gave Endo Pharmaceuticals the go-ahead to weigh in on the government’s administrative proceeding against Impax Laboratories. The case alleges that a 2010 settlement between the companies allowing Endo to introduce a generic version of Impax’s Opana ER had no pro-competitive justifications.
Endo will be allowed to submit a brief opposing the government’s request for relief in its action against Impax that could potentially affect or nullify a second settlement reached between the two pharmaceutical companies in 2017.
The original complaint in 2012, accused Endo in 2012 of working a deal in which they compensated Watson Laboratories “hundreds of millions of dollars” to hold off a generic version of Endo’s Lidoderm patch. It also accused Endo of paying Impax $112 million in 2010 to hold off releasing an authorized generic version of Endo’s painkiller Opana. The FTC alleged Endo’s financial gain by giving it time to transition patients to a new formulation of Opana ER, “thereby maintaining its monopoly power.”
Full Content: Federal Trade Commission and Global Competition Review
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI